A substantial fraction (∼20%) of mammography-detected breast lesions are ductal carcinoma *in situ* (DCIS). As the mammographic appearance of a breast tumour reflects pathological changes of breast anatomy, the biological aggressiveness of a cancer or its precursors is potentially predicted by mammographic characteristics. An association between mammographic findings and histology, especially when microcalcifications are present has been observed ([@bib8]; [@bib18]; [@bib3]) and the mammographic traits of various tumour types have been linked to the nature of the underlying pathological changes ([@bib4]; [@bib2]; [@bib22]). Mammographic characteristics have been proposed as a prognostic indicator of breast cancer ([@bib21]; [@bib15], [@bib16]; [@bib23]; [@bib17]). A higher risk of breast cancer death has been shown in the presence of casting-type calcifications as compared with cancers not associated with this mammographic abnormality ([@bib10]; [@bib16]; [@bib23]; [@bib17]; [@bib11]). However, the long-term clinical results predominantly derive from studies on invasive carcinomas.

We report the results from a case-cohort study nested within the national Swedish randomised trial of breast conservation in DCIS, SweDCIS ([@bib5]), in which 1046 women were randomly assigned to radiotherapy or control only, following a sector resection for DCIS between 1987 and 1999. We studied the association between the mammographic appearances of microcalcifications, in particular, the casting-type calcification and the risk of local recurrence in the ipsilateral breast and the relationships between the presence of casting-type calcifications and other tumour characteristics.

Subjects and methods
====================

Enrolment, randomisation and interventions in SweDCIS
-----------------------------------------------------

The design and main results of SweDCIS have been described earlier ([@bib5]). In short, to be eligible for SweDCIS, women had to have undergone breast-conserving surgery for histologically proven DCIS occupying a quadrant or less of the breast and with a clinically negative examination of the axilla. Exclusion criteria included Paget\'s disease of the nipple, invasive carcinoma or intracystic carcinoma *in situ*, on-going pregnancy, history of previous or concurrent malignancy (except basal cell carcinoma and treated carcinoma *in situ* of the uterine cervix). After full informed consent, the women were randomly assigned to RT or to control. The trial was nationwide, and randomisation was stratified for health care region. The treating physician reported baseline data. The regional ethics committees approved the study.

After a sector resection of the breast, the women were randomised to postoperative radiotherapy of the breast or control only. A macroscopic surgical margin of 1 cm to the sides was aimed for. The removed skin overlying the lesion and/or Scarpas\' fascia constituted the ventral border and the pectoral fascia, the dorsal border. Microscopically free margins were not requested but achieved in 80% of all removed surgical specimens (11% had positive margins and 8.5% unknown margins) as reported in the clinical pathology reports and on the case record form of the study. The specification dose of radiotherapy was 50 Gy, given in 25 fractions over 5 weeks or 54 Gy given in two series with a gap of 2 weeks. No woman was lost to follow-up.

Study design
------------

The present study builds on the patients included in a case-cohort study of histopathological risk factors for ipsilateral breast events (IBE) ([@bib13]), with the addition of cases with IBE occurring up to the end of 31 July 2005. Women eligible as cases had an IBE of DCIS or invasive cancer that was identified through a full monitoring of all original medical records through the 31 July 2005. Women eligible as a sample from the cohort -- henceforth called subcohort -- were all women included in the study. Selection of the subcohort was done from the baseline data at inclusion irrespective of any future IBE. For each of the participating six Health Care Regions, the selection was done by day of birth in the month, with different days randomly allocated to the patients from each region. We aimed to sample at least 20% of the cohort. Three dedicated breast pathologists examined the microscopic slides of the subcohort and all cases included in the study by [@bib13]. Cases of IBE occurring between 2002 and 31 July 2005 were not histopathologically re-evaluated. The study set-up is illustrated in the flowchart in [Figure 1](#fig1){ref-type="fig"}.

Follow-up and clinical events
-----------------------------

Patients were initially followed by biannual clinical examination and yearly mammograms for five years and thereafter by clinical examination and mammography on a yearly basis. All medical records were monitored. Furthermore, we searched all inpatient, mammography and pathologic laboratory registers for indications of any IBE in the cohort.

All events in the ipsi- or contralateral breast or in the ipsilateral axilla were based on either clinical or mammography diagnosis subsequently morphologically verified after surgical excision. Causes of death were extracted from the Swedish Cause of Death Registry.

Mammographic re-evaluation
--------------------------

We attempted to retrieve all mammographic films from the preoperative evaluation. One experienced radiologist (LT) evaluated the preoperative work-up mammograms and microfocus magnification images, when available. He was blinded to randomisation arm and all clinical data including case status.

The classification of the mammographic findings was based on a description of the mammographic appearance of *in situ* carcinoma subtypes ([@bib18]). DCIS cases with no mammographically demonstrable calcifications are called 'special forms\' and are detected either by finding an asymmetric density with architectural distortion or a dominant mass (intracystic papillary lesion) or through galactographic findings. Approximately 75--80% of the mammographically demonstrable *in situ* breast carcinomas have one or more of the following malignant type calcifications: (1) The crushed stone-like (pleomorphic) calcifications are the most frequently occurring; (2) The 'powdery\', cotton ball-like calcifications and (3) The casting -ype, linear, branching calcifications appear in similar proportions.

Statistical methods
-------------------

Cox proportional hazards models, stratified and adjusted according to specifications in Table 3, were assumed for DCIS and invasive ipsilateral events, and hazard ratios and variance estimates for the case-cohort design were determined according to [@bib14]. Technically, this was done by using the statistical programme package R ([@bib12]) and following [@bib20]. The analyses of prognostic factors were stratified on randomisation arm (radiotherapy *vs* no radiotherapy) to allow for different baseline hazards in the control and RT groups.

The cumulative incidence was determined according to [@bib6] adapted to fit the case-cohort design (the subcohort as previously described under 'Study design\') rather than the cohort design, by replacing the numbers at risk by estimated numbers at risk.

In all our time-to-event analyses, follow-up was censored at the end of the study or death if no recurrence had occurred previously. When analysing DCIS events only, follow-up was also censored if a woman first experienced an invasive recurrence. In analyses of invasive events only, follow-up was censored if a woman first had a DCIS recurrence. In estimation of cumulative incidence, death without recurrence was always considered as a competing event to IBE, and when estimating the cumulative incidence of DCIS as first recurrence, an invasive recurrence was also considered as a competing event, and vice versa when estimating the cumulative incidence of an invasive recurrence as first event.

Results
=======

[Table 1](#tbl1){ref-type="table"} displays the clinical, tumour and mammographic characteristics of the patients included in the subcohort and in the case-series. The numbers in each subset vary according to availability of histopathological data and of mammograms. As expected, the women in the case series had a somewhat lower age at diagnosis, lower proportion screen-detected lesions, larger tumours, not completely excised DCIS, higher proportion of invasive lesions at review, more necrosis and a distribution towards higher grades. In addition, the women in the case series more often had a casting-type mammographic pattern.

We analysed the associations between mammographic pattern and histopathological characteristics in the subcohort population with DCIS as per our previous review ([@bib13]) ([Figure 1](#fig1){ref-type="fig"}, [Table 2](#tbl2){ref-type="table"}). As the subcohort is a random sample of the whole SweDCIS trial, this analysis represents these associations in the underlying study base regardless of case status. When calcifications of any type were present, necrosis was more prevalent. Age seemed to be a determinant for these features as they were more frequently found in younger women. Lesions in women with crushed stone or casting-type microcalcifications also showed higher tumour grade, had a larger diameter and more often had involved margins after surgery ([Table 2](#tbl2){ref-type="table"}).

[Table 3](#tbl3){ref-type="table"} shows the relative risks (RRs) with 95% confidence intervals (CIs) obtained in Cox models of risk of ipsilateral *in situ* or invasive breast recurrence. All models are stratified by randomisation arm (radiotherapy *vs* no radiotherapy) in SweDCIS and take the largest patient group -- women with crushed stone-like calcifications -- as a reference. For all types of IBEs, casting-type and crushed stone-like calcifications implied elevated risks in the non-adjusted model. The RR comparing women with no calcifications to those with casting-type was 2.10 (the ratio of RR: s 1.36/0.65 in [Table 3](#tbl3){ref-type="table"}, with 95% CI 0.92 -- 4.8), but with a modest 36% relative difference in risk between crushed stone and casting-type calcifications.

When we studied *in situ* and invasive recurrences separately ([Table 3](#tbl3){ref-type="table"}), the risk was isolated to the risk of *in situ* recurrence. In the non-adjusted model, women with casting-type calcifications had a 22.8-times higher risk (1.98/0.09, [Table 3](#tbl3){ref-type="table"}, with 95% CI 2.93--177.21) than those without a calcification to develop an *in situ* recurrence. Adjustment for age, lesion size and margin status changed the pattern modestly, but the RR for ipsilateral *in situ* associated with a casting type-was still 16.4 (95% CI 2.2-140) compared with women without calcifications ([Table 3](#tbl3){ref-type="table"}).

Graphs of cumulative incidence of IBEs, by randomisation arm and mammographic patterns characterised as casting-type, crushed stone and others grouped together ([Figure 2](#fig2){ref-type="fig"}) show again a higher risk associated with crushed stone or casting calcifications ([Figure 2](#fig2){ref-type="fig"}, upper panels). The high risk for women with casting-type calcifications pertained mainly to *in situ* local recurrences (lefthand panel, lower panels [Figure 2](#fig2){ref-type="fig"}). The pattern was similar for crushed stone-like calcifications.

Although radiotherapy in relative terms had similar effects in all subsets ([Figure 2](#fig2){ref-type="fig"}), in absolute terms, the risk of recurrence was still high in women with casting-type calcifications despite postoperative radiotherapy. The cumulative incidence graphs of *in situ* local recurrence indicates that the recurrences present at a steady rate during the first four years of follow-up after diagnosis in the casting calcification group, irrespective of whether radiotherapy was given or not (lower left panel, [Figure 2](#fig2){ref-type="fig"}). However, the cumulative incidence graphs for invasive recurrence indicates that the rate of invasive recurrences is stable over time at least during the first 8 years of follow up (middle panels, [Figure 2](#fig2){ref-type="fig"}).

When the cumulative incidence per randomisation arm and by mammographic pattern was analysed by the median age (56 years at diagnosis) in the study, it appeared that in women ⩽56 years of age, radiotherapy had less impact on local recurrence than in women \>56 years of age, especially when casting-type calcifications were present on the mammogram ([Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}). In younger women with casting-type calcifications, the cumulative incidence curve for those randomized to radiotherapy even tended to be above those allocated to control (left hand panels [Figure 3](#fig3){ref-type="fig"}), but there was no statistically significant interaction between age as a continuous variable and radiotherapy for all IBE (*P*=0.69) or for *in situ* IBE (*P*=0.80). On the other hand, the high risk for women over 56 years of age with casting calcifications was strongly reduced in the study arm randomized to RT (left hand panels [Figure 4](#fig4){ref-type="fig"}).

In the study as a whole, only 14 patients died from breast cancer with no statistically significant difference between the randomisation arms or between the mammographic pattern groups.

Discussion
==========

We found an increased risk of IBE in patients with crushed stone and casting-type calcifications. Both types of calcifications were associated with a marked predominance with recurrence of ipsilateral *in situ* carcinomas. The findings -- notably from a randomized study design -- also indicate that radiotherapy had low efficacy in women with casting-type calcifications and ⩽56 years at diagnosis, but clearly reduced risk in women over 56 years. In women with casting-type calcifications on the mammogram, *in situ* recurrences presented at a high and constant rate during the first 4 years of follow-up. In contrast, invasive recurrences had a more constant occurrence rate over the 8 years of observation. As expected, there was a strong association between casting-type calcifications and necrosis as well as histological nuclear grade 3, but the risk estimates derived from the mammographic pattern did not disappear with a correction for clinical or histopathological variables.

The analyses are based on a large randomized trial with long and complete follow-up. The case-cohort study design exhibits a statistical power close to that of analysing the full trial as it uses all events of interest. As the subcohort is a random sample of the entire trial, the randomized design is not compromised. The majority of the mammograms from the subcohorts and cases outside the subcohort were obtained and re-evaluated, and only one experienced radiologist reviewed the mammograms. As we could not locate all mammograms and despite that the number of cases is comparatively large, there were a limited number of cases in the subgroups obtained by stratification, which entails a limited statistical power and precision in the subgroup analyses. We also had data from a previous review and re-evaluation of the participants\' histopathologal slides done by three experienced breast pathologists ([@bib13]). There may have been a misclassification of the primary lesion for some of the cases added after 2001, that is some four per cent may have had an invasive tumour ([@bib1]).

Several studies ([@bib9]; [@bib15] and [@bib17]; [@bib10]; [@bib21]; [@bib23]) have shown that mammography could be helpful at the time of diagnosis to identify women with high-risk invasive disease. However, very few or hardly any data on mammographic patterns in relation to local recurrence were found for women with DCIS only. Moreover, comparison between studies is hampered by different classifications of mammographic patterns and microcalcifications that have been used.

A study by [@bib15] proposed that the presence of casting-type calcifications may be a vital prognostic factor in small screen-detected breast cancers. Women with 1--9 mm and 10--14 mm invasive tumours associated with casting-type calcifications on the mammogram had a 26-year survival of 72 and 55%, respectively, whereas women with 1--9 mm and 10--14 mm invasive cancers without casting type calcifications had a 95% *vs* 88% 26-year disease-specific survival, respectively. Grade 3 DCIS is usually associated with casting-type calcification. Similar conclusions were reached by [@bib21] when combining the casting type and crushed stone-like calcifications. They investigated 96 women with 1--9 mm invasive breast cancers with or without calcification, and indicating that casting or pleomorphic calcifications are associated with a significantly higher risk of death, irrespective of nodal status and histological malignancy grade. [@bib9] investigated the presence of residual microscopic disease after breast-conservation surgery. They found an association between casting calcifications and prediction of local recurrence. The only independent preoperative mammographic feature was casting-type calcifications as indicated by others ([@bib10]; [@bib23]).

The fact that crushed stone and particularly casting-type calcifications were associated with *in situ* recurrence only is of considerable interest. Hypothetically, these patterns often are associated with *in situ*, multifocal, diffuse *in situ* growth and can be difficult to excise completely. This hypothesis is corroborated by the rapidly (within four years after surgery) recurring lesions. Also, casting-type calcifications have been associated with multifocality in invasive breast cancer ([@bib7]). However, in our study, the RR associated with risk of an *in situ* recurrence was only marginally altered when disease extent and margin status were taken into account. Another tentative explanation is that this mammographic pattern reveals a susceptibility to develop new *in situ* lesions. A third possibility is that the lesions associated with casting-type calcifications histologically initially exhibit features of *in situ* carcinomas even when recurring, but in reality they behave like invasive tumours by ductneogenesis ([@bib19]). They are thus biologically aggressive and underway to progress to invasive carcinomas. This hypothesis gets some support from the studies of mammographic patterns in invasive cancer cited above. In this study, the histopathological evaluation was not designed with this question in mind and we cannot directly address the ductneogenesis hypothesis.

The indication that age affects responsiveness to radiotherapy in women with casting-type lesions coincides with other findings from this study ([@bib13]; [@bib5]). First, casting-type calcifications are associated with necrosis and we previously found less effect of radiotherapy in the presence of necrosis ([@bib13]). We hypothesised that this was due to less effect of radiotherapy in tissue with low oxygen supply. Second, we found a substantial effect of radiotherapy in terms of absolute risk reduction in older women, but less so in younger women in the last update of SweDCIS ([@bib5]). It may be clinically important to study if this age-effect is mainly explained by the difference in responsiveness in the group of women with casting-type calcifications as indicated by the findings in the present study. The cumulative incidence curves for *in situ* recurrences by randomisation to radiotherapy may imply resistance to radiotherapy in women ⩽56 years and with casting-type calcifications. As our data come from a randomized trial, the findings related to radiotherapy are not confounded by indication and may well therefore reflect a clinically highly relevant effect. However, we caution that the findings relate to a subgroup analysis with limited statistical precision and should not be taken to guide practice, but as findings to be validated in other cohorts and further understood by biological studies.

In conclusion, crushed stone-like and especially casting-type calcifications are associated with higher risk of *in situ* recurrence after surgery for *in situ* breast carcinoma. This high risk is well alleviated by radiotherapy. However, our findings indicate that radiotherapy for these lesions may be less effective in younger women. Both our previous findings on lower responsiveness to radiotherapy in relation to age and these new findings relating to mammographic calcifications indicate that these clinical characteristics together with other factors can help to define groups of women with DCIS where mastectomy with or without reconstruction is a safer option than breast conservation.

This study was supported by the Swedish Cancer Society and Västerbotten County, Sweden. Holmberg and Gamso was also supported by Cancer Research UK.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.

The authors declare no conflict of interest.

![Flow chart of the selection of women to the subcohort and the case-series with ipsilateral breast events (IBE).](bjc201326f1){#fig1}

![Cumulative incidence of local recurrences by mammographic pattern in all women; the three upper panels describe all (invasive plus *in situ*) recurrences in the radiotherapy (RT) arm and the control (Ctrl) arm by type of mammographic pattern of the primary lesion; the three middle panels describe invasive recurrences in the radiotherapy (RT) arm and the control (Ctrl) arm, the lower panels the *in situ* recurrences in the respective arm of the SweDCIS trial by mammographic pattern of the primary. Women with no calcifications, and those with architectural distortion, galactography findings, and with powdery calcifications are grouped together as 'Other\'.](bjc201326f2){#fig2}

![Cumulative incidence of local recurrences by mammographic pattern in women ⩽56 years of age at diagnosis; the three upper panels describe all (invasive plus *in situ*) recurrences in the radiotherapy (RT) arm and the control (Ctrl) arm by type of mammographic pattern of the primary lesion; the three middle panels describe invasive recurrences in the radiotherapy (RT) arm and the control (Ctrl) arm, the lower panels the *in situ* recurrences in the respective arm of the SweDCIS trial by mammographic pattern of the primary. Women with no calcifications, and those with architectural distortion, galactography findings, and with powdery calcifications are grouped together as 'Other\'.](bjc201326f3){#fig3}

![Cumulative incidence of local recurrences by mammographic pattern in women \>56 years of age at diagnosis; the three upper panels describe all (invasive plus *in situ*) recurrences in the radiotherapy (RT) arm and the control (Ctrl) arm by type of mammographic pattern of the primary lesion; the three middle panels describe invasive recurrences in the radiotherapy (RT) arm and the control (Ctrl) arm, the lower panels the *in situ* recurrences in the respective arm of the SweDCIS trial by mammographic pattern of the primary. Women with no calcifications, and those with architectural distortion, galactography findings and powdery calcifications are grouped together as 'Other\'.](bjc201326f4){#fig4}

###### Clinical, mammographic and histopathological characteristics of all study subjects. Numbers in each subset vary depending on availability of slides and mammograms

                                                                                   **Subcohort**   **Cases outside subcohort**         
  ------------------------------------------------------------------------------- --------------- ----------------------------- ------ --------
  **Age, mean (s.d.)**                                                                 56.7                   (9.2)              55.4   (9.4)
  **Randomized to, No. (%)**                                                                                                           
  RT                                                                                    148                  (51.6)               44    (29.1)
  Control                                                                               139                  (48.4)              107    (70.9)
  **Detection mode, No. (%)**                                                                                                          
  Screening detected                                                                    220                  (76.9)              108    (71.5)
  Not screening detected                                                                66                   (23.1)               43    (28.5)
  **Palpation, No. (%)**                                                                                                               
  Palpable                                                                              73                   (25.4)               38    (25.2)
  Not palpable                                                                          208                  (72.5)              109    (72.2)
  Unknown                                                                                6                    (2.1)               4     (2.6)
  **Tumour size, No. (%)**                                                                                                             
  \<10                                                                                  64                   (22.3)               23    (15.2)
  10--19                                                                                111                  (38.7)               42    (27.8)
  20--39                                                                                70                   (24.4)               43    (28.5)
  40+                                                                                   18                    (6.3)               16    (10.6)
  Missing data                                                                          24                    (8.4)               27    (17.9)
  **Surgical margins, No. (%)**                                                                                                        
  Pathological margins clear                                                            199                  (81.6)               86    (70.5)
  Pathological margins positive                                                         26                   (10.7)               25    (20.5)
  Pathological margins unknown or missing                                               19                    (7.8)               11    (9.0)
  **Mammographic pattern, No. (%)**                                                                                                    
  No calcifications                                                                     32                   (13.1)               9     (7.4)
  Architectural distortion/galactography                                                22                    (9.0)               8     (6.6)
  Powdery                                                                               25                   (10.2)               7     (5.7)
  Crushed stone-like                                                                    126                  (51.6)               68    (55.7)
  Casting-type                                                                          39                   (16.0)               30    (24.6)
  **Cancer type**[a](#t1-fn1){ref-type="fn"}**, No. (%)**                                                                              
  Paget/microinvasive/invasive                                                          11                    (3.8)               12    (9.9)
  Benign/ADH/LCIS                                                                       24                    (8.4)               3     (2.5)
  Missing/bad material                                                                  22                    (7.7)               8     (6.6)
  DCIS                                                                                  229                  (80.1)               98    (81.0)
  **Necrosis among DCIS-patients**[b](#t1-fn2){ref-type="fn"}**, No. (%)**                                                             
  Necrosis                                                                              169                  (73.8)               85    (86.7)
  No necrosis                                                                           60                   (26.2)               13    (13.3)
  **Nuclear grade among DCIS patients**[b](#t1-fn2){ref-type="fn"}**, No. (%)**                                                        
  NG=1                                                                                  20                    (8.7)               3     (3.1)
  NG=2                                                                                  95                   (41.5)               32    (32.7)
  NG=3                                                                                  114                  (49.8)               63    (64.3)

Only determined for patients included in the pathology study.

Only determined for patients included in the pathology study with a pathologically verified DCIS.

###### Associations between histopathological characteristics and mammographic patterns in a subcohort of 198 patients with DCIS

                               **No calcifications** ***N*** **(%)**   **Architectural distortion/galactography** ***N*** **(%)**   **Powdery** ***N*** **(%)**   **Crushed stone-like** ***N*** **(%)**   **Casting type*****N*** **(%)**   **Sum** ***N*****(%)**                                     
  --------------------------- --------------------------------------- ------------------------------------------------------------ ----------------------------- ---------------------------------------- --------------------------------- ------------------------ ----- -------- ---- -------- ----- ---------
  All DCIS in subcohort                         22                                               (11.1)                                         14                                (7.1)                                  20                          (10.1)           106   (53.5)   36   (18.2)   198   (100.0)
  Necrosis                                       9                                               (6.1)                                           5                                (3.4)                                  14                          (9.5)            86    (58.5)   33   (22.4)   147   (100.0)
  No necrosis                                   13                                               (25.5)                                          9                                (17.6)                                  6                          (11.8)           20    (39.2)   3    (5.9)    51    (100.0)
  NG=1                                           4                                               (25.0)                                          2                                (12.5)                                  2                          (12.5)            8    (50.0)   0    (0.0)    16    (100.0)
  NG=2                                          16                                               (19.3)                                          7                                (8.4)                                  14                          (16.9)           43    (51.8)   3    (3.6)    83    (100.0)
  NG=3                                           2                                               (2.0)                                           5                                (5.1)                                   4                          (4.0)            55    (55.6)   33   (33.3)   99    (100.0)
  Age \<50                                       4                                               (10.8)                                          2                                (5.4)                                   7                          (18.9)           20    (54.1)   4    (10.8)   37    (100.0)
  Age 50--57                                     4                                               (6.0)                                           1                                (1.5)                                   9                          (13.4)           41    (61.2)   12   (17.9)   67    (100.0)
  Age 58--64                                     3                                               (7.1)                                           3                                (7.1)                                   1                          (2.4)            24    (57.1)   11   (26.2)   42    (100.0)
  Age 65+                                       11                                               (21.2)                                          8                                (15.4)                                  3                          (5.8)            21    (40.4)   9    (17.3)   52    (100.0)
  Tumour size \<15 mm                           15                                               (15.0)                                          7                                (7.0)                                   9                          (9.0)            57    (57.0)   12   (12.0)   100   (100.0)
  Tumour size 15⩾mm                              7                                               (8.4)                                           5                                (6.0)                                   7                          (8.4)            42    (50.6)   22   (26.5)   83    (100.0)
  Missing tumour size                            0                                               (0.0)                                           2                                (13.3)                                  4                          (26.7)            7    (46.7)   2    (13.3)   15    (100.0)
  Surgical margins clear                        17                                               (10.4)                                         12                                (7.3)                                  18                          (11.0)           93    (56.7)   24   (14.6)   164   (100.0)
  Surgical margins positive                      3                                               (15.8)                                          0                                (0.0)                                   2                          (10.5)            9    (47.4)   5    (26.3)   19    (100.0)
  Unknown/missing                                2                                               (13.3)                                          2                                (13.3)                                  0                          (0.0)             4    (26.7)   7    (46.7)   15    (100.0)

###### Relative risks and 95% CIs for ipsilateral recurrence obtained in Cox Proportional Hazards Models. All models are stratified for randomisation arm in SweDCIS. 'Other\' category denotes architectural distortion and galactography findings

                                                                 **All ipsilateral**   **Ipsilateral DCIS**   **Ipsilateral Invasive**                        
  ------------------------------------------------------------- --------------------- ---------------------- -------------------------- -------------- ------ --------------
  Crushed stone-like calcification[a](#t3-fn1){ref-type="fn"}            Ref                                            Ref                             Ref          
  Casting-type calcification[a](#t3-fn1){ref-type="fn"}                 1.36               (0.79--2.35)                 1.98             (1.08--3.65)   0.69   (0.30--1.62)
  Powdery calcification[a](#t3-fn1){ref-type="fn"}                      0.54               (0.24--1.24)                 0.59             (0.19--1.80)   0.49   (0.17--1.40)
  No calcification[a](#t3-fn1){ref-type="fn"}                           0.65               (0.31--1.36)                 0.09             (0.01--0.66)   1.30   (0.58--2.91)
  Other[a](#t3-fn1){ref-type="fn"}                                      0.62               (0.27--1.43)                 0.34             (0.09--1.35)   0.96   (0.37--2.53)
  Crushed stone-like calcification[b](#t3-fn2){ref-type="fn"}            Ref                                            Ref                             Ref          
  Casting-type calcification[b](#t3-fn2){ref-type="fn"}                 1.41               (0.81--2.45)                 2.03             (1.09--3.76)   0.72   (0.31--1.71)
  Powdery calcification[b](#t3-fn2){ref-type="fn"}                      0.48               (0.21--1.11)                 0.54             (0.18--1.64)   0.43   (0.15--1.22)
  No calcification[b](#t3-fn2){ref-type="fn"}                           0.67               (0.32--1.41)                 0.09             (0.01--0.68)   1.35   (0.60--3.05)
  Other[b](#t3-fn2){ref-type="fn"}                                      0.60               (0.26--1.40)                 0.33             (0.08--1.32)   0.93   (0.35--2.48)
  Crushed stone-like calcification[c](#t3-fn3){ref-type="fn"}            Ref                                            Ref                             Ref          
  Casting-type calcification[c](#t3-fn3){ref-type="fn"}                 1.05              ( 0.56--1.95)                 1.31             (0.64--2.66)   0.61   (0.24--1.53)
  Powdery calcification[c](#t3-fn3){ref-type="fn"}                      0.31               (0.12--0.82)                 0.31             (0.09--1.14)   0.30   (0.10--0.94)
  No calcification[c](#t3-fn3){ref-type="fn"}                           0.60               (0.28--1.31)                 0.08             (0.01--0.61)   1.23   (0.54--2.84)
  Other[c](#t3-fn3){ref-type="fn"}                                      0.35               (0.12--0.99)                 0.15             (0.03--0.77)   0.67   (0.21--2.09)

Stratified on treatment (RT/control).

Adjusted for age (continuous) and stratified on treatment.

Adjusted for age (continuous), tumour size (grouped \<15 mm, \>15 mm, missing information) and margins and stratified on treatment.
